Register for our free email digests:
Latest From SurgiQuest Inc.
At $1.2 billion, Q4 device financing was the second-lowest quarter of 2015; M&A dollar volume was also low, but included multiple deals across various cardiovascular markets. Diagnostics financing was also down in Q4, totaling $403 million; acquisitions were worth $441 million.
Sanofi pushed ahead to advance its leadership in diabetes in a partnership with Hanmi; Pfizer bought Allergan in biopharma's biggest M&A to date, at $160bn. Boston Pharma's $600m financing contributed greatly to the early-stage venture category's 50% share of total financing.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced October-November 2015.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in November 2015.
Surgical Equipment & Devices
- Minimally or Less Invasive
- Surgical Equipment & Devices
- Therapeutic Areas
- Metabolic Disorders
- North America
- Parent & Subsidiaries
- SurgiQuest Inc.
- Senior Management
Kurt Azarbarzin, CEO
Christine Antalik, VP, Fin.
Carlos Babini, EVP, International Sales & Mktg.
Dominick Mastri , Dir., R&D
- Contact Info
Phone: (203) 799-2400
488 Wheelers Farms Rd.
Milford, CT 06461
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.